Genetic protein TmSm(T34A) enhances sensitivity of chemotherapy to breast cancer cell lines as a synergistic drug to doxorubicin

Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie
Yuxin XuXingyuan Ma

Abstract

In order to eliminate common side effects to cancer patients and resistance from chemotherapy, a genetic protein TmSm(T34A) was investigated as a sensitizer to doxorubicin. The results indicated TmSm(T34A) enhanced the sensitivity of three breast cancer cell lines to doxorubicin with low dose, and reduced the dose of doxorubicin significantly in contrast to common effective dose. As a synergistic therapy, the TmSm(T34A) also caused strongest apoptotic activity in MCF-7, and the possible molecular mechanisms were explored primarily. The research showed the TmSm(T34A) is promising to be a potential drug in strengthening therapy effects of breast cancer chemotherapy.

References

Mar 28, 2002·Proceedings of the National Academy of Sciences of the United States of America·Jennifer TranRobert S Kerbel
Oct 5, 2002·Cellular and Molecular Life Sciences : CMLS·N ZaffaroniM G Daidone
May 30, 2003·The EMBO Journal·Hiroyuki MarusawaJohn C Reed
Jun 26, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Geoffrey I Shapiro
Oct 19, 2004·The Journal of Clinical Investigation·Takehiko DohiDario C Altieri
Jan 11, 2005·The Journal of Pathology·D B Longley, P G Johnston
Jun 21, 2006·Archives of Otolaryngology--head & Neck Surgery·Hiromi KojimaYoshinobu Manome
Aug 29, 2006·Current Opinion in Cell Biology·Dario C Altieri
Sep 12, 2006·Current Opinion in Cell Biology·Susanne M A LensRené H Medema
Mar 31, 2007·International Journal of Radiation Oncology, Biology, Physics·Kwang Woon KimBo Lu
Jul 10, 2007·Food and Chemical Toxicology : an International Journal Published for the British Industrial Biological Research Association·L Y ShiuK W Kuo
Dec 14, 2007·Nature Reviews. Cancer·Dario C Altieri
May 16, 2009·Current Cancer Drug Targets·Pepita Giménez-BonaféRicardo Pérez-Tomás
May 28, 2010·Journal of Cellular Physiology·A B Di StefanoM Todaro
Sep 18, 2010·Neoplasma·M AdamkovJ Rajcany

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptotic Caspases

Apoptotic caspases belong to the protease enzyme family and are known to play an essential role in inflammation and programmed cell death. Here is the latest research.

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Breast Cancer: Chemo-Resistance

Some cancers are difficult to treat and aggressive including the "triple-negative" breast cancer. This type of cancer is chemoresistant even before chemotherapy begins. Here are the latest discoveries chemo-resistance in breast cancer.

Related Papers

Expert Opinion on Therapeutic Targets
Marzia PennatiNadia Zaffaroni
Cancer Treatment Reviews
Bríd M RyanMichael J Duffy
Cancer Letters
Michael J DuffyBríd M Ryan
© 2021 Meta ULC. All rights reserved